- American City Business Journals•5 hours ago
A startup based at UMass Boston’s Venture Development Center that’s developed a unique way of getting molecules inside living cells has announced a $16 million investment and the hiring of a former Novartis executive as chief business officer. SQZ Biotech, headed by 29-year-old co-founder and CEO Armon Sharei, says the Series B investment was led by two venture firms, NanoDimension and Polaris Partners. Boston-based Polaris was behind a $5 million round the company received in June 2015 , and partner Amy Schulman (also executive chairwoman of SQZ) said that the company has made “remarkable progress” since it was founded in 2013.
- Investor's Business Daily•20 hours ago
Amgen will likely beat Eli Lilly, Alder and Teva to market with an antibody-blocking migraine med.
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||78.87 x 200|
|Ask||78.88 x 300|
|Day's Range||78.28 - 79.06|
|52wk Range||69.90 - 95.11|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||28.22|
|Avg Vol (3m)||1,299,531|
|Dividend & Yield||2.72 (3.35%)|